Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can cutting carbs and a diabetes drug help kidneys?

NCT ID NCT06094231

Disease control Sponsor: Department of Nephrology Clinic Ottakring Vienna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This small pilot study tested whether a low-carb diet (50-100 grams of carbs per day) combined with the diabetes drug dapagliflozin could improve blood sugar control in people with chronic kidney disease and prediabetes or type 2 diabetes. Four participants were split into two groups: one received the diet plus drug, the other received standard care plus the drug. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

4 people

The number who actually took part.

Started

Sep 2023

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chronic Kidney Disease Stage KDIGO 3a-4 (eGFR eGFR 25-59 mg/min/1.73m²) * Prediabetes or Diabetes according to the Guideline of the American Diabetes Association (HbA1c \>5,7 percent, or fasting glucose values \> 100 mg/dL, or glucose levels \> 140 mg/dL at 2h during an oral glucose tolerance test) * Being overweight (Body Mass Index \> 25.0 kg/m²) * Being able to independently: * \- Perform measurements of blood glucose and ketone levels * \- Use a continous glucose monitor * \- Contact the study team Exclusion Criteria: * Patients who are allergic to SGLT-2-Inhibitors * Patients with autoimmune diabetes (Typ 1 or LADA) * Patients with pancreoprivic diabetes * Patients with a history of ketoacidosis or lactate acidosis * Patients with severe hypoglycemic episodes in the 6 moths prior to inclusion * Patients with bariatric surgery (in the past or planed) * Patients with nephritic range proteinuria (\>3,5g of Albumin/day) * Patients with active malignant diseases * Pregnant or breastfeeding patients

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome diabetes mellitus Obesity obesity disorder Overweight prediabetes syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney diseases Diabetes mellitus Overweight and obesity Prediabetes

Contacts and locations

Locations

  • 6th Medical Department with Nephrology and Dialysis, Clinik Ottakring

    Vienna, 1160, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.